Drug intelligence / Profile preview

Oralgam

Development stage: Phase 2
Lead developer: PediaMed Pharmaceuticals
Modality: Recombinant Proteins and Enzymes
Administration: Oral

Overview

Oralgam is a pharmaceutical drug containing human immunoglobulin, developed by PediaMed Pharmaceuticals. It is currently being investigated in a Phase II clinical trial for its efficacy in treating persistent gastrointestinal problems, such as diarrhea, constipation, abdominal pain, and bloating, in pediatric patients with autistic disorder. Human immunoglobulins are proteins that play a crucial role in the body's immune system, providing antibody-mediated responses against foreign antigens and modulating immune responses.

Brand names: Oralgam
Other names: human immunoglobulin

Targets

FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)Complement (Complement system)

Beyond the preview

Go deeper on Oralgam.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oralgam.

Explore the full profile